Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

Technology Scientific & Technical Instruments
RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair... see more

TSXV:RP - Post Discussion

Replicel Life Sciences Inc > It's over the Judgement has been released
View:
Post by Ingiboy on Oct 16, 2023 8:21pm

It's over the Judgement has been released

 

2023-10-16 19:09 ET - News Release

 

Mr. Andrew Schutte reports

REPLICEL LIFE SCIENCES ANNOUNCES ARBITRATION DECISION

On Monday, Oct. 16, 2023, RepliCel Life Sciences Inc. received the final award related to its continuing arbitration proceedings with Shiseido Co. Ltd. The tribunal dismissed RepliCel's claims finding that Shiseido validly terminated the collaboration and technology transfer agreement dated effective as of July 9,

2013. Management is currently considering the impact of the decision and
assessing its options.

 


2023-10-16 19:09 ET - News Release

 

Mr. Andrew Schutte reports

REPLICEL LIFE SCIENCES ANNOUNCES ARBITRATION DECISION

On Monday, Oct. 16, 2023, RepliCel Life Sciences Inc. received the final award related to its continuing arbitration proceedings with Shiseido Co. Ltd. The tribunal dismissed RepliCel's claims finding that Shiseido validly terminated the collaboration and technology transfer agreement dated effective as of July 9, 2013. Management is currently considering the impact of the decision and assessing its options.


Comment by BellEnd on Oct 16, 2023 10:19pm
This post has been removed in accordance with Community Policy
Comment by Year3000 on Oct 17, 2023 1:43am
Oh no... what happens next, where do we go from here?  Is everyone holding or selling?  can they go to court again to stop shiseido using their technology?  Mia the dermal injector still going to market?  Are we bust?  
Replicel Life Sciences Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities